Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697319 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01697319 is a Phase 2 study that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 16 participants.
The verdict
NCT01697319, a Phase 2 study, was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.
Interventions
- DRUG BMN 110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01697319
The ClinicalTrials.gov registry entry for NCT01697319 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMN 110 is the first listed.
NCT01697319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01697319 about?
NCT01697319 is a clinical study titled "Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation". The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.
What is the current status of trial NCT01697319?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2012-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01697319?
The interventions under investigation include: BMN 110 (DRUG).
Who is sponsoring clinical trial NCT01697319?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.